Apolipoprotein A-I, apolipoprotein B, high-sensitivity C-reactive protein and severity of coronary artery disease in tunisian population

Cardiovascular Pathology

Volumn 21, Issue 6, 2012, Pages 455-460

  Hrira, Mohamed Yahia ^a,b   Kerkeni, Mohsen ^c   Hamda, Ben Khaldoun ^d   Chahed, Henda ^a,b   Ferchichi, Salima ^a,b   Addad, Faouzi ^d   Limam, Halima Ben ^a   Miled, Abdelhedi ^a,b  

^a FARHAT HACHED HOSPITAL   (Tunisia)

^b UNIVERSITY OF MONASTIR   (Tunisia)

^c Laboratory of Biochemistry   (Tunisia)

^d FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

ApoA I; ApoB; Coronary artery disease; hs CRP; Severity of CAD

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANGIOGRAPHY; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CORONARY STENOSIS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TUNISIA;

EID: 84868588183     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2012.02.009     Document Type: Article

References (42)

1. E. Abderrahim, K. Zouaghi, and H. Hedri Renal replacement therapy for diabetic end-stage renal disease. Experience of a Tunisian Hospital Centre Diabetes Metab 27 2001 584 590
2. H. Ben Maïz, E. Abderrahim, F. Ben Moussa, R. Goucha, and C. Karoui Epidemiology of glomerular diseases in Tunisian from 1975 to 2005. Influence of changes in healthcare and society Bull Acad Natl Med 190 2006 403 416
3. E. Counil, N. Cherni, M. Hkarrat, A. Achour, and H. Trimech Trends of incidence dialysis patients in Tunisia between 1992 and 2001 Am J Kidney Dis 51 2008 463 470
4. J.L. Anderson, J.B. Muhlestein, and B.D. Horne Plasma homocysteine predicts mortality independently of tradictional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease Circulation 102 2000 1227 1232
5. M. Kerkeni, F. Added, M. Ben Farhat, A. Miled, F. Trivin, and K. Maaroufi Hyperhomocysteinaemia and parameters of antioxidative defence in Tunisian patients with coronary heart disease Ann Clin Biochem 45 2008 193 198
6. G. Walldius, I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, and E. Steiner High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2001 2026 2033
7. INTERHEART Study Investigators Effect of potentially modiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
8. H. Toss, B. Lindahl, A. Siegbahn, and L. Wallentin Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease Circulation 96 1997 4204 4210
9. A.Y. Tiong, and D. Brieger Inflammation and coronary heart disease Am Heart J 150 2005 11 18
10. G. Liuzzo, L.M. Biasucci, and J.R. Gallimore The prognostic value of C-re-active protein and serum amyloid A protein in severe un-stable angina N Engl J Med 331 1994 417 424
11. F. Haverkate, S.G. Thompson, S.D. Pyke, J.R. Gallimore, M.B. Pepys for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group Production of C-reactive protein and risk of coro-nary events in stable and unstable angina Lancet 349 1997 462 466
12. J.S. Zebrack, J.B. Muhlestein, B.D. Horne, J.L. Anderson for the Intermountain Heart Collaboration Study Group C-reactive protein and angiographic coronary artery dis-ease: independent and additive predictors of risk in sub-jects with angina J Am Coll Cardiol 39 2002 632 637
13. M. Erren, H. Reinecke, and R. Junker Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arter-ies Arterioscler Thromb Vasc Biol 19 1999 2355 2363
14. N. Rifai, R. Joubran, H. Yu, M. Asmi, and M. Jouma Inflamma-tory markers in men with angiographically documented coronary heart disease Clin Chem 45 1999 1967 1973
15. R.R. Azar, G. Aoun, D.B. Fram, D.D. Waters, A.H.B. Wu, and F.J. Ki-ernan Relation of C-reactive protein to extent and se-verity of coronary narrowing in patients with stable angi-na pectoris or abnormal exercise tests Am J Cardiol 86 2000 205 208
16. A. Hoffmeister, D. Rothenbacher, and U. Bazner Role of novel mark-ers of inflammation in patients with stable coronary heart disease Am J Cardiol 87 2001 262 266
17. P. Ellerbe, G.L. Myers, and G.R. Cooper A comparison of results for cholesterol in human serum obtained by the Reference Method and by the Definitive Method of the National eference System for cholesterol Clin Chem 36 1990 370 375
18. F.M. Sacks The apolipoprotein story Atheroscler Suppl 7 2006 23 27
19. G.R. Warnick, T. Nguyen, and A.A. Albers Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol Clin Chem 31 1985 217 222
20. D.J. Rader, J.M. Hoeg, and H.B. Brewer Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease Ann Intern Med 120 1994 1012 1025
21. Baudner S, Bienvenu J, et al. The certrification of matrix reference for immunochemical measurement of 14 humman serum proteins. CRM 470 Brussels: Community Bureau of reference, commission of the European communities. BCR information. Reference materials. 1993; report EUR 15243 EN ISSN 1018-5593° 1-172.
22. H. Ben Ramdhane, H. Haouala, and A. Belhani Epidemiological transition and health impact of cardiovascular disease in Tunisia Tunis Med 83 2005 1 7
23. D. Wood Established and emerging cardiovascular risk factors Am Heart J 141 2001 S49 57
24. P.G. McGovern, D.R. Jacobs, E. Shahar, D.K. Arnett, A.R. Folsom, H. Blackburn, and R.V. Luepker Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey Circulation 104 1 2001 19 24
25. M.B. Pepys, and G.M. Hirschfield C-reactive protein: a critical update J Clin Invest 111 2003 1805 1812
26. M. Torzewski, C. Rist, R.F. Mortensen, and T.P. Zwaka C-reactive protein in the arterial intima: role of C-reactive protein receptor dependent monocyte recruitment in atherogenesis Arterioscler Thromb Vasc Biol 20 2000 2094 2099
27. S. Fichtscherer, G. Rosmbingr, D.H. Walter, and S. Breur Elevated C-reactive protein and improved endothelial reactivity in patients with coronary artery disease Circulation 102 2000 1000 1016
28. S.K. Venugopalan, S. Devaraj, I. Yuhana, and P. Shaul Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells Circulation 106 2002 1439 1441
29. T.P. Zwaka, V. Hombach, and J. Torzewski C-reactive protein mediated low density lipoprotein uptake by macrophages: implications for atheroscle-rosis Circulation 103 2001 1194 1197
30. E. Paffen, H.L. Vos, and R.M. Bertina C-reactive protein does not directly induce tissue factor in human monocytes Arterioscler Thromb Vasc Biol 24 5 2004 975 981
31. M.A. Sardo, S. Campo, G. Mandraffino, C. Saitta, A. Bonaiuto, M. Castaldo, M. Cinquegrani, G. Pizzimenti, and A. Saitta Tissue factor and monocyte chemoattractant protein-1 expression in hypertensive individuals with normal or increased carotid intima-media wall thickness Clin Chem 54 5 2008 814 823
32. S. Devraj, U. Singh, and I. Jialal The evolving role of C-reactive protein in atherothrombosis Clin Chem 55 2009 229 238
33. X. Wang, D. Liao, U. Bharadwaj, M. Li, Q. Yao, and C. Chen C-reactive protein inhibits cholesterol efflux from human macrophage derived foam cells Arterioscler Thromb Vasc Biol 28 2008 519 526
34. W. Koenig Is hs CRP back on board? Implications from the JUPITER trial Clin Chem 55 2009 216 218
35. B. Goswami, V. Mallika, M. Rajappa, S. Kumar, and D.K. Shukla Apo-B/Apo-A-I ratio: a better discriminator of coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction Acta Cardiol 63 2008 749 755
36. B. Lamarche, J.P. Despres, S. Moorjani, B. Cantin, G.R. Dagenais, and P.J. Lupien Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular study) Am J Cardiol 75 1995 1189 1195
37. K. Williams, A.D. Sniderman, N. Sattar, R. D'Agostino, L.E. Wagenknecht, and S.M. Haffner Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS) Circulation 108 2003 2312 2316
38. J.S. Volek, M.L. Fernandez, R.D. Feinman, and S.D. Phinney Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome Prog Lipid Res 47 2008 307 318
39. R. Natarajan, and J.L. Nadler Lipid inflammatory mediators in diabetic vascular disease Arterioscler Thromb Vasc Biol 24 2004 1542 1548
40. E. Lopez-Garcia, M.B. Schulze, J.B. Meigs, J.E. Manson, N. Rifai, M.J. Stampfer, W.C. Willett, and F.B. Hu Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction J Nutr 135 2005 562 566
41. S.N. Han, L.S. Leka, A.H. Lichtenstein, L.M. Ausman, E.J. Schaefer, and S.N. Meydani Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercho-lesterolemia J Lipid Res 43 2002 445 452
42. H. Sun, T. Koike, T. Ichikawa, K. Hatakeyama, M. Shiomi, B. Zhang, S. Kitajima, M. Morimoto, T. Watanabe, Y. Asada, Y.E. Chen, and J. Fan C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance Am J Pathol 167 2005 1139 1148